Amgen's Imdelltra slashes small cell lung cancer death risk by 58% in major trial

Key points

• Median overall survival reached 21.1 months for the combination therapy versus 12.7 months for Imfinzi alone.
• The risk of disease progression or death dropped by 66%, with median progression-free survival improving to 7.4 months from 1.9 months.
• Nearly 80% of patients on the combination regimen were alive at one year, compared to 53% on Imfinzi alone.
• Safety data showed manageable side effects, with only 0.4% of patients experiencing severe cytokine release syndrome.
• Amgen is now testing Imdelltra in earlier treatment stages and in limited-stage disease to expand its patient base.

Background

Small cell lung cancer (SCLC) is a fast-growing, aggressive disease with roughly 31,000 new U.S. cases annually, 60-70% of which are diagnosed at an extensive stage. Historically, median survival for these patients ranges from eight to 10 months, making it more lethal than pancreatic cancer. While recent news has highlighted shifts in cancer mortality rankings, such as colorectal cancer overtaking lung cancer as the second leading cause of death in the U.S., SCLC remains a critical area for therapeutic innovation due to its rapid progression and limited treatment options.

How outlets are covering it

CNBC and Fierce Pharma both highlight the 'watershed' nature of the results, with Amgen’s chief medical officer calling the data 'transformational.' Fierce Pharma notes that these results rival the recent success of Revolution Medicines’ Rasonque in pancreatic cancer, potentially displacing Jazz Pharmaceuticals’ Zepzelca as a standard maintenance therapy. NBC News emphasizes the 'practice-changing' potential for patients, even those with metastatic disease. While all outlets agree on the magnitude of the survival benefit, Fierce Pharma provides deeper analysis on the competitive landscape, noting that Imdelltra’s success is driving interest in DLL3-targeted competitors like Zai Lab’s zocilurtatug pelitecan and emerging B7-H3 antibody-drug conjugates. CNBC focuses more on the commercial trajectory, noting Imdelltra’s rapid sales growth and potential to become a blockbuster drug.

Why it matters

This trial offers a significant improvement in survival for a cancer type with historically poor outcomes, potentially converting a fatal disease into a manageable chronic condition for some patients. The success of T-cell engagers in solid tumors like SCLC validates a new therapeutic approach and could lead to earlier use of these drugs in treatment protocols. For the industry, it signals a shift in standard care and intensifies competition among biopharma companies targeting the DLL3 protein and other immune pathways in lung cancer.

What to watch

Amgen is conducting Phase 3 trials to test Imdelltra in first-line induction and maintenance settings, as well as in limited-stage SCLC following chemoradiotherapy. The company expects longer follow-up data from the current trial to show even greater survival benefits, potentially matching the 37.9-month median survival seen in earlier Phase 1b studies. Competitors are also advancing DLL3-targeted therapies, which may influence future treatment guidelines and market share.